BioArctic

BioArctic Interest Coverage

The Interest Coverage Ratio of BioArctic (BIOA B.ST) as of Sep 27, 2026 is 424.63. In the previous year, Interest Coverage Ratio was -7.01 — a change of -6,161.09% (higher).

Interest Coverage

424.63

YoY

-6,161.09%

Last updated:

Interest Coverage Ratio of BioArctic is 2026 424.63 . Interest Coverage Ratio of BioArctic was 2025 -7.01 . It decreases by -6,161.09% higher compared to the previous year.

The BioArctic Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
128.93 SEK
Jan 1, 2019
60.10 SEK
Jan 1, 2020
-83.91 SEK
Jan 1, 2021
-617.38 SEK
Jan 1, 2022
-3.34 SEK
Jan 1, 2023
21.14 SEK
Jan 1, 2024
-7.01 SEK
Jan 1, 2025
424.63 SEK
The BioArctic Interest Coverage history
YEARInterest CoverageYoY
424.63-6,161.09%
-7.01-133.15%
21.14-732.27%
-3.34-99.46%
-617.38+635.72%
-83.91-239.62%
60.10-53.38%
128.93+156.88%
50.19+670.25%
6.52-96.77%
201.83—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Interest Coverage Ratio of BioArctic is 424.63 in 2026.

Interest Coverage Ratio of BioArctic changed from -7.01 to 424.63, representing a -6,161.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio BioArctic since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — BioArctic

All Key Metrics — BioArctic